Explore the words cloud of the NEXIM project. It provides you a very rough idea of what is the project "NEXIM" about.
The following table provides information about the project.
TARGIMMUNE THERAPEUTICS AG
|Coordinator Country||Switzerland [CH]|
|Total cost||71˙429 €|
|EC max contribution||50˙000 € (70%)|
1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
|Duration (year-month-day)||from 2019-05-01 to 2019-10-31|
Take a look of project's partnership.
|1||TARGIMMUNE THERAPEUTICS AG||CH (BASEL)||coordinator||50˙000.00|
In spite of enormous medical progress, aggressive forms of cancer remain one of the leading causes of death across the globe. Metastasized prostate, lung, breast and colon cancer account for a combined mortality of approximately 0,8 M lives in Europe per year. Immunotherapies, activating patient’s own immune system to target and destroy tumor cells, have shown enormous promise in the treatment of metastatic forms of cancer, creating a huge market with a €100B potential in 2022. However, these drugs are only effective in 15-25% of patients, and their use is associated with severe side effects. Therefore, there is an unmet medical need for next-generation of cancer immunotherapies with improved safety and consistent efficacy in a broader patient population.
TargImmune, is a Switzerland based company with a mission to develop novel targeted immuno-oncology drugs that will improve the treatment of patients with aggressive tumors. Using our proprietary treatment technology based on the targeted intracellular delivery of an RNA-analogue inside the tumor, we will provide novel systemic immune therapy for metastasized cancer with less side effects and improved effectiveness across all patient populations. Currently we have 3 drugs in development for prostate, breast cancer and solid tumors. All potential pipeline candidates address a highly attractive immune-oncology market, with the total addressable market for our first asset of €1.7B. The product is predicted to generate €466M of cumulative annual revenues through 10 % royalties over sales in the first 5 years, as a part of licensing deal with a large pharmaceutical company.
After initial investment round, we currently seek for additional funding to further develop our pipeline candidates. In the NEXIM project, we will finalize an investor-ready business plan, required to ensure additional investments. The project will also include an analysis of the competitor and investor landscape and market positioning.
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NEXIM" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (email@example.com) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "NEXIM" are provided by the European Opendata Portal: CORDIS opendata.
Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any contRead More
Smart Nursing BraRead More
IOT and cloud computing for online medical analysis service platformRead More